Flora Growth Corp. (FLGC)
USD 0.63
(5.0%)
USD 0.63
(5.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.67 Million USD | -11.37% |
| 2022 | 4.14 Million USD | 209.64% |
| 2021 | 1.33 Million USD | 106.16% |
| 2020 | 649 Thousand USD | -51.16% |
| 2019 | 1.32 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 5.69 Million USD | 55.17% |
| 2024 Q2 | 5.61 Million USD | -1.47% |
| 2023 FY | 3.67 Million USD | -11.37% |
| 2023 Q3 | 3.11 Million USD | -7.7% |
| 2023 Q1 | 3.94 Million USD | -4.88% |
| 2023 Q4 | 3.67 Million USD | 17.81% |
| 2023 Q2 | 3.37 Million USD | -14.31% |
| 2022 Q4 | 4.14 Million USD | 24.68% |
| 2022 Q3 | 3.32 Million USD | -10.41% |
| 2022 Q1 | - USD | -100.0% |
| 2022 Q2 | 3.7 Million USD | 0.0% |
| 2022 FY | 4.14 Million USD | 209.64% |
| 2021 Q1 | - USD | -100.0% |
| 2021 FY | 1.33 Million USD | 106.16% |
| 2021 Q2 | 346 Thousand USD | 0.0% |
| 2021 Q4 | 1.33 Million USD | 0.0% |
| 2020 Q4 | 571 Thousand USD | 0.0% |
| 2020 Q3 | 571 Thousand USD | 137.77% |
| 2020 Q2 | 240.14 Thousand USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 649 Thousand USD | -51.16% |
| 2019 FY | 1.32 Million USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.321% |
| Theratechnologies Inc. | 58.96 Million USD | 93.773% |
| Safety Shot Inc | 1.54 Million USD | -137.06% |
| Cosmos Health Inc. | 12.42 Million USD | 70.444% |
| Cronos Group Inc. | 2.53 Million USD | -44.57% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 99.487% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 89.891% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 96.923% |
| Universe Pharmaceuticals INC | 5.48 Million USD | 33.023% |
| ProPhase Labs, Inc. | 21.38 Million USD | 82.825% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -503.947% |
| Dynavax Technologies Corporation | 256.91 Million USD | 98.571% |
| Radius Health, Inc. | 365.31 Million USD | 98.995% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -38.699% |
| Alvotech | 1.07 Billion USD | 99.659% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -458.305% |
| Alpha Teknova, Inc. | 30.45 Million USD | 87.944% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 78.321% |
| SCYNEXIS, Inc. | 15.08 Million USD | 75.65% |
| Harrow Health, Inc. | 190.5 Million USD | 98.072% |
| Biofrontera Inc. | 5.39 Million USD | 31.987% |
| DURECT Corporation | 20.74 Million USD | 82.3% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 91.158% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 98.835% |
| OptiNose, Inc. | 131.74 Million USD | 97.213% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -213.042% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 96.284% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 80.074% |
| SIGA Technologies, Inc. | 1.46 Million USD | -150.818% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 97.183% |
| Shineco, Inc. | 29.65 Million USD | 87.618% |
| Phibro Animal Health Corporation | 525.45 Million USD | 99.301% |
| Procaps Group S.A. | 285.93 Million USD | 98.716% |
| TherapeuticsMD, Inc. | 8 Million USD | 54.129% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -6039.75% |
| Viatris Inc. | 18.12 Billion USD | 99.98% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -458.305% |
| Rockwell Medical, Inc. | 13.43 Million USD | 72.677% |
| Incannex Healthcare Limited | 373 Thousand USD | -884.45% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 75.729% |
| Tilray Brands, Inc. | 387.31 Million USD | 99.052% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 99.455% |
| PetIQ, Inc. | 468.3 Million USD | 99.216% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.143% |
| Journey Medical Corporation | 17.73 Million USD | 79.289% |
| Alimera Sciences, Inc. | 67.39 Million USD | 94.552% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | 55.634% |
| Assertio Holdings, Inc. | 40.91 Million USD | 91.025% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -237.595% |
| Embecta Corp. | 1.63 Billion USD | 99.776% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -255.43% |
| Procaps Group, S.A. | 285.93 Million USD | 98.716% |
| PainReform Ltd. | 86 Thousand USD | -4169.767% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 89.622% |
| Hempacco Co., Inc. | 13.72 Million USD | 73.245% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 99.373% |
| Alvotech | 1.07 Billion USD | 99.659% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 99.405% |
| Kamada Ltd. | 8.74 Million USD | 58.029% |
| Indivior PLC | 281.6 Million USD | 98.696% |
| Currenc Group, Inc. | 31.94 Million USD | 88.505% |
| Evoke Pharma, Inc. | 5 Million USD | 26.56% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -255.43% |
| Evolus, Inc. | 126.54 Million USD | 97.098% |
| HUTCHMED (China) Limited | 86.13 Million USD | 95.737% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 99.411% |
| Akanda Corp. | 3.99 Million USD | 8.172% |